دورية أكاديمية
Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status
| العنوان: | Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status |
|---|---|
| المؤلفون: | Alafandi, A, van Garderen, K A, Klein, S, van der Voort, S R, Rizopoulos, D, Nabors, L, Stupp, R, Weller, Michael, Gorlia, T, Tonn, J-C, Smits, M |
| المصدر: | Alafandi, A; van Garderen, K A; Klein, S; van der Voort, S R; Rizopoulos, D; Nabors, L; Stupp, R; Weller, Michael; Gorlia, T; Tonn, J-C; Smits, M (2023). Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status. European Journal of Cancer, 188:122-130. |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2023 |
| المجموعة: | University of Zurich (UZH): ZORA (Zurich Open Repository and Archive |
| مصطلحات موضوعية: | Clinic for Neurology, 610 Medicine & health, Glioblastoma, Magnetic resonance imaging, Overall survival, Radiotherapy, Tumour burden |
| الوصف: | PURPOSE: We retrospectively evaluated the association between postoperative pre-radiotherapy tumour burden and overall survival (OS) adjusted for the prognostic value of O$^{6}$-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with newly diagnosed glioblastoma treated with radio-/chemotherapy with temozolomide. MATERIALS AND METHODS: Patients were included from the CENTRIC (EORTC 26071-22072) and CORE trials if postoperative magnetic resonance imaging scans were available within a timeframe of up to 4weeks before radiotherapy, including both pre- and post-contrast T1w images and at least one T2w sequence (T2w or T2w-FLAIR). Postoperative (residual) pre-radiotherapy contrast-enhanced tumour (CET) volumes and non-enhanced T2w abnormalities (NT2A) tissue volumes were obtained by three-dimensional segmentation. Cox proportional hazard models and Kaplan Meier estimates were used to assess the association of pre-radiotherapy CET/NT2A volume with OS adjusted for known prognostic factors (age, performance status, MGMT status). RESULTS: 408 tumour (of which 270 MGMT methylated) segmentations were included. Median OS in patients with MGMT methylated tumours was 117 weeks versus 61weeks in MGMT unmethylated tumours (p < 0.001). When stratified for MGMT methylation status, higher CET volume (HR 1.020; 95% confidence interval CI [1.013-1.027]; p < 0.001) and older age (HR 1.664; 95% CI [1.214-2.281]; p = 0.002) were significantly associated with shorter OS while NT2A volume and performance status were not. CONCLUSION: Pre-radiotherapy CET volume was strongly associated with OS in patients receiving radio-/chemotherapy for newly diagnosed glioblastoma stratified by MGMT promoter methylation status. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0959-8049 |
| العلاقة: | https://www.zora.uzh.ch/id/eprint/240196/1/PIIS095980492300223X.pdfTest; info:pmid/37235895; urn:issn:0959-8049 |
| DOI: | 10.5167/uzh-240196 |
| DOI: | 10.1016/j.ejca.2023.04.021 |
| الإتاحة: | https://doi.org/10.5167/uzh-24019610.1016/j.ejca.2023.04.021Test https://www.zora.uzh.ch/id/eprint/240196Test/ https://www.zora.uzh.ch/id/eprint/240196/1/PIIS095980492300223X.pdfTest |
| حقوق: | info:eu-repo/semantics/openAccess ; Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) ; http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: | edsbas.B0AE1431 |
| قاعدة البيانات: | BASE |
| تدمد: | 09598049 |
|---|---|
| DOI: | 10.5167/uzh-240196 |